Dedicated to discovery & development of important medicines to transform the lives of patients & their families
Clinical Trials
Global Clinical Development
Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class cancer therapies.
Learn more on ClinicalTrials.gov.
49 Clinical Trials Ongoing
-
AML/MDS
Lisaftoclax (APG-2575)
Study of APG-2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: AML/MDS -
AML/MDS
Lisaftoclax (APG-2575)
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: AML/MDS -
AML/MDS
Lisaftoclax (APG-2575)
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: AML/MDS -
AML/MDS
Alrizomadlin (APG-115)
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
MOLECULE: Alrizomadlin (APG-115)
CONDITION: AML/MDS -
AML/MDS
Alrizomadlin (APG-115)
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
MOLECULE: Alrizomadlin (APG-115)
CONDITION: AML/MDS -
Anemia
APG-5918
A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
MOLECULE: APG-5918
CONDITION: Anemia -
CLL
Lisaftoclax (APG-2575)
Study of APG-2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: CLL -
CLL
Lisaftoclax (APG-2575)
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: CLL -
CLL
Lisaftoclax (APG-2575)
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: CLL -
CLL
Lisaftoclax (APG-2575)
Global Trial in APG-2575 for Patients With CLL/SLL
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: CLL -
CLL
Lisaftoclax (APG-2575)
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: CLL -
CML
Olverembatinib (HQP1351)
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
MOLECULE: Olverembatinib (HQP1351)
CONDITION: CML -
CML
Olverembatinib (HQP1351)
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
MOLECULE: Olverembatinib (HQP1351)
CONDITION: CML -
CML
Olverembatinib (HQP1351)
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
MOLECULE: Olverembatinib (HQP1351)
CONDITION: CML -
CML
Olverembatinib (HQP1351)
Study of Olverembatinib (HQP1351) in Patients With CP-CML (POLARIS-2)
MOLECULE: Olverembatinib (HQP1351)
CONDITION: CML -
CML or Ph+ ALL
Olverembatinib (HQP1351)
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
MOLECULE: Olverembatinib (HQP1351)
CONDITION: CML or Ph+ ALL -
HBV
APG-1387
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
MOLECULE: APG-1387
CONDITION: HBV -
HBV
APG-1387
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
MOLECULE: APG-1387
CONDITION: HBV -
Healthy volunteers
Olverembatinib (HQP1351)
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
MOLECULE: Olverembatinib (HQP1351)
CONDITION: Healthy volunteers -
Healthy volunteers
Lisaftoclax (APG-2575)
The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: Healthy volunteers -
Hematologic Malignancies
Lisaftoclax (APG-2575)
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: Hematological malignancies -
Hematologic Malignancies
Lisaftoclax (APG-2575)
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: Hematological malignancies -
Lymphoma
Pelcitoclax (APG-1252)
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Lymphoma -
MM
Lisaftoclax (APG-2575)
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: MM -
MM
Lisaftoclax (APG-2575)
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: MM -
MM
Lisaftoclax (APG-2575)
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: MM -
Myelofibrosis
Pelcitoclax (APG-1252)
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Myelofibrosis -
NSCLC
Pelcitoclax (APG-1252)
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: NSCLC -
Ph+ALL
Olverembatinib (HQP1351)
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
MOLECULE: Olverembatinib (HQP1351)
CONDITION: Ph+ ALL -
Ph+ALL
Olverembatinib (HQP1351)
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.
MOLECULE: Olverembatinib (HQP1351)
CONDITION: Ph+ ALL -
SCLC
Pelcitoclax (APG-1252)
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: SCLC -
SCLC
Pelcitoclax (APG-1252)
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: SCLC -
SLE
Lisaftoclax (APG-2575)
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: SLE -
Solid tumors or Lymphoma
APG-5918
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
MOLECULE: APG-5918
CONDITION: Solid tumor or Lymphoma -
Solid tumors
Olverembatinib (HQP1351)
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
MOLECULE: Olverembatinib (HQP1351)
CONDITION: Solid tumors -
Solid tumors
Alrizomadlin (APG-115)
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Solid tumors -
Solid tumors
Alrizomadlin (APG-115)
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Solid tumors -
Solid tumors
Alrizomadlin (APG-115)
APG-115 in Salivary Gland Cancer Trial
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Solid tumors -
Solid tumors
Alrizomadlin (APG-115)
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Solid tumors -
Solid tumors
Alrizomadlin (APG-115)
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Solid tumors -
Solid tumors
APG-2449
APG-2449 in Patients With Advanced Solid Tumors
MOLECULE: APG-2449
CONDITION: Solid tumors -
Solid tumors
APG-1387
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
MOLECULE: APG-1387
CONDITION: Solid tumors -
Solid tumors
APG-1387
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
MOLECULE: APG-1387
CONDITION: Solid tumors -
Solid tumors
APG-1387
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
MOLECULE: APG-1387
CONDITION: Solid tumors -
Solid tumors
Pelcitoclax (APG-1252)
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Solid tumors -
Solid tumors
Pelcitoclax (APG-1252)
APG-1252 in Patients With SCLC or Advanced Solid Tumors
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Solid tumors -
T-PLL / Lymphoma
Alrizomadlin (APG-115)
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
MOLECULE: Alrizomadlin (APG-115)
CONDITION: T-PLL / Lymphoma -
CML
Olverembatinib (HQP1351)
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
MOLECULE: Olverembatinib (HQP1351)
CONDITION: CML -
Solid tumors
Lisaftoclax (APG-2575)
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
MOLECULE: Lisaftoclax (APG-2575)
CONDITION: Solid tumors